详情页

当前位置：首页 > 详情页

Trial of IPGDP Regimen Chemotherapy in Patients With Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type

8| 链接全文 |

文献详情

编号/登记号：

注册时间：

研究开始时间：

项目类型：

本院角色：

多中心研究：

招募状态：

试验分期：

研究疾病/适应症：

研究类型：

研究负责人：

研究参与人：

研究单位： [1]Chinese Academy of Medical Sciences [2]Tianjin Medical University Cancer Institute and Hospital [3]First Hospital of China Medical University [4]The Second Affiliated Hospital of Dalian Medical University [5]Hebei Medical University Fourth Hospital [6]Qilu Hospital of Shandong University [7]Shandong Cancer Hospital and Institute [8]Nanfang Hospital of Southern Medical University [9]Guangdong Provincial People's Hospital [10]People's Hospital of Guangxi [11]Xuzhou Medical University [12]Shanxi Province Cancer Hospital [13]Shanxi Dayi Hospital [14]Zhangzhou Municipal Hospital of Fujian Province [15]307 Hospital of PLA

研究目的：

The first Part: recruiting untreated ENKL patients with extensive stage I or limited stage II disease (only referring to patients with the invasion of Waldeyer's ring and cervical lymph nodes) . Patients are randomly divided into two arms, IPGDP regimen chemotherapy followed by radiotherapy or radiotherapy followed by IPGDP regimen chemotherapy. IPGDP regimen for both arms are 3 cycles. And the chemotherapy is repeated every 3 weeks.. The second part: recruiting extensive stage II ,stage III-IV, relapsed or refractory ENKL patients. Patients receive 6 cycles of IPGDP regimen chemotherapy. And the chemotherapy is repeated every 3 weeks.